Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paracetamol + phenylephrine + ascorbic acid
- Development stage
- Unknown
- Lead developer
- Kusum Healthcare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed-dose **combination drug** containing paracetamol, phenylephrine hydrochloride, and ascorbic acid, mainly used for the symptomatic treatment of acute respiratory infections, including cold and influenza-like syndromes. - **Paracetamol** is an analgesic and antipyretic that works primarily through **inhibition of prostaglandin synthesis in the central nervous system**, reducing fever and relieving pain[3][4][5]. - **Phenylephrine** is a sympathomimetic agent (direct alpha-adrenergic agonist) that produces **vasoconstriction**, reducing swelling of the nasal mucosa and relieving nasal congestion[3][4][5]. - **Ascorbic acid** (Vitamin C) is included to compensate for potential depletion during viral infections, acts as an antioxidant, and may support increased resistance to infection[3][4][5]. The combination is administered orally, mainly as granules or powder to be dissolved in water.
- Brand names
- Gripgo Hotmix
- Other names
- paracetamol + phenylephrine + ascorbic acid
02
Targets
ADRA1A (α1A)SLC23A1 (Solute carrier family 23 member 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on paracetamol + phenylephrine + ascorbic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paracetamol + phenylephrine + ascorbic acid.